Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $392.73 million. The enterprise value is $461.90 million.
Important Dates
The next estimated earnings date is Thursday, March 13, 2025, before market open.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 218.18 million shares outstanding. The number of shares has increased by 9.55% in one year.
| Current Share Class | 218.18M |
| Shares Outstanding | 218.18M |
| Shares Change (YoY) | +9.55% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 2.76% |
| Owned by Institutions (%) | 28.49% |
| Float | 197.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.16 |
| Forward PS | 2.38 |
| PB Ratio | -7.79 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.72 |
| EV / EBITDA | 104.74 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52
| Current Ratio | 1.52 |
| Quick Ratio | 1.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | 10.97 |
| Debt / FCF | n/a |
| Interest Coverage | -2.61 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.37% |
| Return on Invested Capital (ROIC) | -32.60% |
| Return on Capital Employed (ROCE) | -23.44% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | -$275,401 |
| Employee Count | 167 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.00% in the last 52 weeks. The beta is 0.74, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +25.00% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 28.80 |
| Average Volume (20 Days) | 1,812,344 |
Short Selling Information
The latest short interest is 14.45 million, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 14.45M |
| Short Previous Month | 17.99M |
| Short % of Shares Out | 6.62% |
| Short % of Float | 7.30% |
| Short Ratio (days to cover) | 5.91 |
Income Statement
In the last 12 months, AKBA had revenue of $169.88 million and -$45.99 million in losses. Loss per share was -$0.23.
| Revenue | 169.88M |
| Gross Profit | 142.93M |
| Operating Income | -33.15M |
| Pretax Income | -40.44M |
| Net Income | -45.99M |
| EBITDA | 4.41M |
| EBIT | -33.15M |
| Loss Per Share | -$0.23 |
Full Income StatementBalance Sheet
The company has $34.02 million in cash and $103.20 million in debt, giving a net cash position of -$69.18 million or -$0.32 per share.
| Cash & Cash Equivalents | 34.02M |
| Total Debt | 103.20M |
| Net Cash | -69.18M |
| Net Cash Per Share | -$0.32 |
| Equity (Book Value) | -50.40M |
| Book Value Per Share | -0.24 |
| Working Capital | 34.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.50 million and capital expenditures -$31,000, giving a free cash flow of -$38.53 million.
| Operating Cash Flow | -38.50M |
| Capital Expenditures | -31,000 |
| Free Cash Flow | -38.53M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
Gross margin is 84.13%, with operating and profit margins of -19.52% and -27.07%.
| Gross Margin | 84.13% |
| Operating Margin | -19.52% |
| Pretax Margin | -27.07% |
| Profit Margin | -27.07% |
| EBITDA Margin | 2.60% |
| EBIT Margin | -19.52% |
| FCF Margin | n/a |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.55% |
| Shareholder Yield | -9.55% |
| Earnings Yield | -11.71% |
| FCF Yield | -9.81% |
Analyst Forecast
The average price target for AKBA is $7.50, which is 316.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.50 |
| Price Target Difference | 316.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 30.30% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -10.09 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.09 |
| Piotroski F-Score | 3 |